Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook - KSWO, Lawton, OK- Wichita Falls, TX: News, Weather, Sports. ABC, 24/7, Telemundo -

Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

http://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html

The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable unmet clinical need. Valued at US$10 billion and with a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes.

The cosy carve up of the market between Pfizer's Spiriva (tiotropium) and GSK's Advair/Serotide (fluticasone propionate/salmeterol), which currently account for 75% of sales globally, will be challenged by new entrants that provide better patient adherence, improve lung function, tackle inflammation and reduce exacerbations of the disease.

Why is COPD causing such excitement?

There is considerable industry and investor excitement about COPD treatment developments. Which of the new products will find favour with clinicians? What regulatory hurdles must they overcome? Do they offer a real clinical improvement over current therapies? Stripping away the hype and harnessing the real world insights from leading US and European KOL's, this Therapy Trends analysis critically examines the products and research and exposes the real potential. For example:

In September 2013, Novartis' Ultibro (glycopyrronium/indacaterol) was the first once daily fixed-dose LABA/LAMA to be approved, with promising research results and positive KOL opinion. However, approved dosages of the indacterol element may be lower in the US, which could affect efficacy and take up. Regulatory delay with the FDA is likely to hand the advantage GSK, Boehringer Ingelheim and Almirall/Forest all of whom are likely to bring LABA/LAMA combinations to the US market before Novartis.
In May 2013, GlaxoSmithKline's Breo/Relvar (fluticasone furoate/vilanterol), the first once-daily ICS/LABA was approved, but there are questions over whether it offers clinical value compared with Symbicort and Advair/Serodtide. However, the tide could turn if the product could become the first COPD therapy to gain a mortality claim if the outcome of the SUMMIT trial is positive. In the words of one KOL: "Let's assume that this study is positive. Then the whole field would change dramatically. This would cause an avalanche."
Takeda's Daxas/Daliresp (roflumilast) was the first, and remains the only, oral PDE-IV inhibitor available but sales are hampered by poor tolerability, unpleasant side effects, variable US formulary coverage and restrictions on use in some EU markets. Chiesi's CHF 6001 (Phase II) inhaled PDE-IV inhibitor is showing promising and is "extremely well tolerated in extended safety studies."

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative COPD market forecast look no further than FirstWord's Therapy Trends: COPD. This comprehensive FirstWord research is available in two comprehensive modules:

The KOL Insight: COPD module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe.
The Consensus Outlook: COPD data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections. Key findings are provided in report which brings together data in charts and tables.

KOL Insight

KOL Insight Report
A qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global COPD market informed by in-depth expert views of leading clinicians
Compare the market's key players, products, late-stage pipeline drugs, product positioning, in the context of COPD market trends.

Event Bulletins
Benefit from the latest KOL views about significant event driven changes in COPD treatment trends.

Consensus Outlook

Consensus Report
An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key COPD market forecast parameters drawn from 13 leading analyst and brokerage companies
Chart COPD market size, product sales, market share by company, competitive status and detailed market forecasts

Interactive Analytics File
Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key company, market and product trends

Key Benefits

Therapy Trends KOL Insight: COPD analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:
KOL Insight Report - an in-depth analytical report on COPD treatment trends
Full report updates - issued to you after each and every significant COPD market event
Event Bulletins - the latest KOL views in response to each event

Key Report Features and Benefits
Critical insights on products and market developments from leading US and European clinicians
Complete coverage of all therapeutic approaches
Assessment of current leading COPD products by sub sector
Analysis of late-stage pipeline COPD therapies by sub sector
Competitive evaluation of leading players
Current thinking and trends in the treatment of COPD and emerging approaches such as Muscarinic antagonist/beta2 agonists
Predicted KOL treatment trends and market leaders
Ongoing clinical and market updates

All current therapeutic approaches covered
Long-acting muscarinic antagonists (LAMAs)
Long-acting beta2 agonists (LABAs)
Phosphodiesterase-IV (PDE-IV) inhibitors
Coverage of both their use as monotherapies or in combination

Expert Opinion for Real World Insights

The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

Key Quotes from the Report

"I think what will be in the best interest of the COPD population is that the LABA/LAMA combination becomes accepted as foundation therapy for anyone with more than mild COPD. Patients who have moderate COPD would benefit most from being on a LABA/LAMA combination." Professor Christopher Cooper (US)

"I think we are looking at a major shift. The name of the game here is maximum bronchodilation. We need to provide the maximum bronchodilation as possible. We are working with two different mechanisms of action; so two mechanisms that complement each other so they are not excluding each other, so that they compliment. And that's the market; the way the market is looking and the way the market is shaping up. Everybody is like, 'well, this is probably the way for us to go." Dr Antonio Anzueto (US)

"We desperately need new anti-inflammatory agents. That's what will take us to the next level. And this almost lemming rush that pharmaceutical companies have of doing the same thing as somebody else does so you can be the first to the market with it." Professor Byron Thomashow (US)

"The problem with Relvar/Breo is when you look at the data when they compared their new drug with their old drug there are no convincing differences. From my point of view it's a once-daily Advair. That's all it is." Professor Claus Vogelmeier (Europe)

Consensus Outlook

Use this detailed report and powerful interactive Excel spread sheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: COPD includes the following comprehensive resources:
An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
Timely event-driven market forecast report and data analysis updates over 12 months.

Report features:
Historical COPD sales from 2007–2012
Forecast COPD sales from 2013-2017
Key competitors and drug developers
Current and late-stage pipeline drugs
Future event mapping to forecast data points
Expected impacting factors on global forecasts

Use Consensus Outlook to
Chart predicted market growth and product sales
Map your own market parameters
Tailor your strategic and investment focus
Assess your current and future sales resources
Set proactive launches and branding strategies

Analysts compared
Barclays Capital
Credit Suisse
Deutsche Bank
Goldman & Sachs
International Strategy & Investment
Jefferies
JP Morgan
Merrill Lynch
Morgan & Stanley
Societe Generale
Stifel Nicolaus
UBS
Wells Fargo

Content Highlights and Products Covered
FirstWord Analysis Highlights
Research Methodology
Chronic Obstructive Pulmonary Disease Marketplace
Key Chronic Obstructive Pulmonary Disease Developers
Chronic Obstructive Pulmonary Disease Class Dynamics
Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast
Eklira/Tudorza (aclidinium; Almirall/Forest) forecast
Seebri (glycopyrronium; Novartis) forecast
Ultibro (glycopyrronium/indacaterol; Novartis) forecast
Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast
Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast
Symbicort (budesonide/formoterol; AstraZeneca) forecast
Arcapta/Onbrez (indacaterol; Novartis) forecast
Daliresp/Daxas (roflumilast; Takeda/Forest) forecast
Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast
Aclidinium/formoterol (Almirall/Forest) forecast

Reasons to Buy this Report

KOL, Analysts, Products and Companies

At a glance listings of those who contributed and the rich and varied sources accessed to produce this major analysis of the COPD market and its prospects.

Key Opinion Leaders
Dr Stephen Rennard is Larson Professor in the Department of Internal Medicine and Professor (courtesy) in the Department of Pathology and Microbiology at the University of Nebraska Medical Center
Dr Antonio Anzueto is Professor of Medicine, Pulmonary/Critical Care Medicine at University of Texas Health Science Center, San Antonio
Dr Donald P. Tashkin is Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine at David Geffen School of Medicine at University of California Los Angeles
Dr Edward Eden is Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Dr Byron Thomashow is a Clinical Professor of Medicine at Columbia University Medical Center and an Attending Physician at the New York-Presbyterian Hospital
Professor Christopher Cooper is a Professor of Medicine and Physiology at David Geffen School of Medicine, University of California, Los Angeles
Professor Peter Barnes is a Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London
Dr Marc Miravitlles is Chest Physician & Senior Researcher, Department of Pneumology, Hospital Clinic, Barcelona
Dr Rene Aalbers is Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands
Professor Claus Vogelmeier is a Professor of Medicine and Head of Pulmonary Division at Marburg University Hospital, Germany
Professor Maurizio Luisetti is a Professor of Respiratory Medicine at the University of Pavia, Italy. Professor Pascal Chanez is a Professor of Medicine, Departement des Maladies Respiratoires, INSERM, Aix Marseille Universite, Marseille, France

Analysts
Barclays Capital
Credit Suisse
Deutsche Bank
Goldman & Sachs
International Strategy & Investment
Jefferies
JP Morgan
Merrill Lynch
Morgan & Stanley
Societe Generale
Stifel Nicolaus
UBS
Wells Fargo

Products & Companies Covered
Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)
Eklira/Tudorza (aclidinium; Almirall/Forest)
Seebri (glycopyrronium; Novartis)
Ultibro (glycopyrronium/indacaterol; Novartis)
Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)
Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)
Symbicort (budesonide/formoterol; AstraZeneca)
Arcapta/Onbrez (indacaterol; Novartis)
Daliresp/Daxas (roflumilast; Takeda/Forest)
Anoro (umeclidinium/vilanterol; GlaxoSmithKline)
Aclidinium/formoterol (Almirall/Forest)

Ongoing Benefits

Continually Updated in Response to Market Developments

The world of pharma is ever changing and executives must always be up- to-date with the latest developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends updated offers real commercial advantage. Consider the benefits:

Consider the benefits:
Content will be fully updated in response to market developments such as new product approvals or pivotal research results for 12 months from the date of purchase
Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report
There is no limit and all relevant events will result in an update
You'll receive these updates directly, within days of each event's occurrence
All updates are included in the price

Whatever happens in the market you'll always be able to assess the impact with FirstWord Therapy Trends

Unrivalled Sources Ensure Complete Coverage

Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including:
Exclusive views from leading global experts
Comprehensive consensus research
Live dispatches and critical industry data
Online opinions from 535,000 vetted physicians
Data from over 125 medical conferences each year
Over 2,000 peer-reviewed medical journals
Over 450 pharmaceutical news sources
Contents Consensus Outlook
1.Analysis Highlights
2.Research Methodology
3.Chronic Obstructive Pulmonary Disease Marketplace
4.Key Chronic Obstructive Pulmonary Disease Developers
5.Chronic Obstructive Pulmonary Disease Class Dynamics
6.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast
7.Eklira/Tudorza (aclidinium; Almirall/Forest) forecast
8.Seebri (glycopyrronium; Novartis) forecast
9.Ultibro (glycopyrronium/indacaterol; Novartis) forecast
10.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast
11.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast
12.Symbicort (budesonide/formoterol; AstraZeneca) forecast
13.Arcapta/Onbrez (indacaterol; Novartis) forecast
14.Daliresp/Daxas (roflumilast; Takeda/Forest) forecast
15.Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast
16.Aclidinium/formoterol (Almirall/Forest) forecast

KOL insight

1.Executive summary
2.Introduction
3.Methodology
4.Current chronic obstructive pulmonary disease marketplace
5.Chronic obstructive pulmonary disease overview
5.1.Epidemiology
5.2.Aetiology
5.3.Risk factors
5.4.Symptoms
5.5.Diagnosis
5.6.Chronic obstructive pulmonary disease treatments
5.6.1.COPD treatment landscape
5.6.2.COPD market definition
5.6.3.Current market overview
5.7.Formulary coverage of chronic obstructive pulmonary disease drugs
6.Current therapies
6.1.Key trials with approved therapies
6.1.2.Spiriva (UPLIFT); FEV1 decline and exacerbations
6.1.3.Spiriva (POET-COPD): LAMA v LABA, exacerbations
6.1.4.Advair/Seretide (TORCH): mortality
6.1.5.Seretide (TRISTAN): lung function and exacerbations
6.1.6.Spiriva versus Seretide (INSPIRE): exacerbations
6.1.7.Triple therapy (OPTIMAL): ICS/LABA plus LAMA
6.2.Long-Acting Muscarinic Antagonists (LAMAs)
6.2.1.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)
6.2.2.Eklira/Tudorza (aclidinium; Almirall/Forest)
6.2.3.Seebri (glycopyrronium; Novartis)
6.3.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist combinations
6.3.1.Ultibro (glycopyrronium/indacaterol; Novartis)
6.3.2.Anoro (umeclidinium/vilanterol; GlaxoSmithKline)
6.4.Fixed-dose Inhaled Corticosteroid/Long-Acting Beta2 Agonist (ICS/LABA) combinations
6.4.1.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)
6.4.2.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)
6.4.3.Symbicort (budesonide/formoterol; AstraZeneca)
6.5.Long-Acting Beta2 Agonists (LABAs)
6.5.1.Arcapta/Onbrez (indacaterol; Novartis)
6.5.2.Striverdi (olodaterol; Boehringer Ingelheim)
6.6.Phosphodiesterase-IV (PDE-IV) inhibitors
6.6.1.Daliresp/Daxas (roflumilast; Takeda/Forest)
7.Pipeline therapies
7.1.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist (LAMA/LABA) 7.2.combinations
7.2.1.Tiotropium/olodaterol (Boehringer Ingelheim)
7.2.2.Aclidinium/formoterol (Almirall/Forest)
7.2.3.Glycopyrronium/formoterol (AstraZeneca/Pearl Therapeutics)
7.3.Fixed-dose triple ICS/LAMA/LABA combinations
7.3.1.Chiesi's triple fixed-dose combination
7.3.2.GlaxoSmithKline's Ellipta device: a platform for triple therapies
7.4.Muscarinic antagonists/beta2 agonists (MABAs)

7.5.Novel anti-inflammatories and anti-oxidants
8.Treatment focus
8.1.Unmet needs in chronic obstructive pulmonary disease
8.1.1.Unmet need 1: Novel agents that modify disease progression and/or reduce exacerbations
8.1.2.Unmet need 2: Early detection of COPD
8.1.3.Unmet need 3: Improving patient drug adherence
8.1.4.Unmet need 4: Confirming COPD diagnosis
8.1.5.Unmet need 5: Understanding the mechanism of action of COPD drugs
8.2.Current chronic obstructive pulmonary disease treatment algorithm
8.2.1.GOLD guidelines
8.2.2.NICE guidelines (England and Wales)
8.3.Device is not a deciding factor in selecting treatments
8.4.Current chronic obstructive pulmonary disease treatment practice
8.4.1.Treatment practice: US
8.4.2.Treatment practice: England
8.4.3.Treatment practice: Spain, France, Italy
8.4.4.Prescribing point 1: ICS are widely used to treat COPD
8.4.5.Prescribing point 2: Free-dose ICS are not approved for COPD in the US or EU
8.4.6.Prescribing point 3: FDA's heightened risk attitude towards LABAs
8.4.7.Prescribing point 4: EMA and FDA have approved different doses
9.1.Future chronic obstructive pulmonary disease treatment algorithm
9.2.LAMA/LABAs provide maximum bronchodilation
9.3.LAMA/LABAs introduce a drug sequencing issue
9.4.ICS withdrawal is a key resistor to LAMA/LABA uptake
9.5.Commercial success of Combivent supports LAMA/LABA US uptake
9.6.Comparative data with ICS/LABAs could accelerate clinical adoption of LAMA/LABAs
10.Future treatment landscape
10.1.Smoking cessation vaccines
10.2.Novel vaccines and anti-virals to reduce exacerbations
10.3.Novel endpoints
10.4.Generic drugs
11.Appendix
11.1indication specific sales
11.2.KOL biographies
11.3.KOLs from US
11.4.KOLs from Europe

Read the full report:
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

http://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
KSWO-TV, 1401 SE 60th Street
Lawton, OK 73501

Telephone: (580) 355-7000
Fax: (580) 357-3811
Email: news@kswo.com

All content © Copyright 2000 - 2014 Worldnow and KSWO. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.